Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim(The University of Texas MD Anderson Cancer Center), Jean‐Yves Douillard(Integrated Oncology (United States)), Vera Hirsh(Taipei Veterans General Hospital), Martin Reck(German Center for Lung Research), Kell Østerlind(Zealand University Hospital), Tony Mok(Chinese University of Hong Kong), Scott M. Lippman(UC San Diego Health System), Frances A. Shepherd(University Health Network), Claire Watkins(AstraZeneca (United Kingdom)), Yan Sun(Peking University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Radj Gervais(Centre François Baclesse), Mark V. Sellers(AstraZeneca (United Kingdom)), Long-Yun Li(Peking Union Medical College Hospital), Mei‐Lin Liao(Shanghai Chest Hospital), Alison Armour(AstraZeneca (United Kingdom)), Mark A. Socinski(Florida Hospital Cancer Institute), Elizabeth Lowe(AstraZeneca (United States))
Cited by 1,243
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k